Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IK-1001 in CABG Surgery
NCT00858936Phase 2Terminated
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- May 2009
- Primary completion
- Apr 2010
- Modality
- DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
A Phase 2 trial of sodium sulfide in ischemia-reperfusion injury (IRI), sponsored by Mallinckrodt Pharmaceuticals. Started May 2009; status: terminated.
02
Drugs
sodium sulfide
03
Conditions
ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT00858936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00858936.